Moderna Therapeutics had a record-breaking initial public offering in December but has since tumbled 35% from its debut price to about $15 a share. On Wednesday, Wall Street analysts issued their price targets for Moderna. With the exception of JPMorgan and Barclays, all were above Moderna's $23 IPO price. Watch Moderna trade in real time. The buzzy biotech Moderna broke records with its initial public offering last month, but its track record since has fallen short. Moderna, which is developing messenger RNA-based therapies for cancer, infectious diseases, and more, went public at $23 a share in early December.